Abstract

AbstractMany oil producers in the Rocky Mountains region, USA, make use of electrical submersible pumps (ESP) to assist the lift of produced fluids. This region of the country is well known for its very harsh winters, with outside temperatures as low as −40 °F (−40 °C).ESP failures resulting in increased lifting costs due to workovers, lost oil, and logistics can be caused by many factors, including reservoir solids eroding the ESP or being trapped within the intake and pump stages, mechanical and electrical problems, and scale deposition. ESPs are particularly sensitive to calcium carbonate scale formation due to the extreme skin temperatures that can develop and often require continuous chemical injection to control this problem.Calcium carbonate scale formation in ESPs is a well known contributor to ESP failures. Large pressure drops combined with high temperatures increase the risk of calcium carbonate deposition even in mildly scaling systems. Scale formation on the motor housing acts as insulation, preventing heat transfer from the motor to the well fluids, causing the motor to be insufficiently cooled. Any scale deposition on the pump impellers can cause an imbalance and vibration, degrading pump performance.Continuous scale inhibitor treatment of ESPs to mitigate calcium carbonate scaling is a common practice. However, the choice of scale inhibitor requires careful consideration due to the high skin temperatures that can develop and can lead to inhibitor decomposition. Effective continuous treatment of ESPs during the winter months in regions where very low temperatures can be expected require product formulations capable of withstanding these harsh conditions without significant changes to their physical properties.This paper presents and discusses, with the aid of laboratory and field data, the development and deployment of a thermally stable scale inhibitor suitable for treatment of ESPs that can also be deployed in very cold climates, along with the monitoring tools used to ensure effective treatment.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.